TransThera Sciences (Nanjing) (HKG:2617) said it was looking to raise HK$156.6 million via a share offering, according to a Tuesday filing with the Hong Kong bourse.

The drugmaker is seeking investors for 3.8 million shares priced at HK$40.83 each to raise funds for the development of new indications for its core product tinengotinib.

The shares represent 1.24% of the company's existing H shares and 0.95% of its total issued shares, and 1.23% and 0.94% as enlarged by the offering, respectively.

TransThera recently said that tinengotinib was found to offer benefit to patients in a clinical trial conducted in China.

Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.